Evidence map›Paper›PMID 37718463›Full record

Trial reportThoracic cancer2023

A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer.

Yohei Yabuki, Masaki Hanibuchi, Eiji Takeuchi, Takashi Haku, Takanori Kanematsu, Naoki Nishimura, Yuko Toyoda, Atsushi Mitsuhashi, Kenji Otsuka, Seidai Sato and 6 more

Open access · goldAbstract readMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Yohei YabukiDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Masaki HanibuchiDepartment of Community Medicine for Respirology, Hematology and Metabolism, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Eiji TakeuchiDepartment of Clinical Investigation, National Hospital Organization Kochi Hospital, Kochi, Japan.ORCID 0000-0003-1541-9747
Takashi HakuDepartment of Respiratory Medicine, Tokushima Prefectural Central Hospital, Tokushima, Japan.
Takanori KanematsuDepartment of Respiratory Medicine, Japanese Red Cross Matsuyama Hospital, Matsuyama, Japan.
Naoki NishimuraDepartment of Pulmonary Medicine, St. Luke's International Hospital, Tokyo, Japan.
Yuko ToyodaDepartment of Internal Medicine, Japanese Red Cross Kochi Hospital, Kochi, Japan.ORCID 0000-0002-9124-7978
Atsushi MitsuhashiDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Kenji OtsukaDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Seidai SatoDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Hisatsugu GotoDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Hiroto YonedaDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Hirokazu OginoDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Hiroshi NokiharaDepartment of Respiratory Medicine, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.ORCID 0000-0002-1219-6966
Shinohara TsutomuDepartment of Community Medicine for Respirology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Yasuhiko NishiokaDepartment of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.ORCID 0000-0001-6311-1654
Tokushima University · JPJapanese Red Cross Kochi Hospital · JPMatsuyama Red Cross Hospital · JPNational Center for Global Health and Medicine · JPNational Hospital Organization Kochi National Hospital · JPSt. Luke's International Hospital · JPTokushima Prefectural Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough the incidence of lung cancer in elderly individuals has been increasing in recent years, the number of clinical trials designed specifically for elderly patients with advanced non-small cell lung cancer (NSCLC) is still limited. To fulfill this unmet medical need, we conducted a phase II study to elucidate the efficacy of pemetrexed (PEM) plus bevacizumab (Bev) combination chemotherapy in elderly patients with nonsquamous NSCLC.

methodsA total of 29 elderly patients (≥75 years old) with nonsquamous NSCLC were enrolled in this multicenter, open-label, phase II study, and 27 patients were finally analyzed. PEM at 500 mg/m

resultsThe median age at initiating chemotherapy was 80 years old. Almost all patients (92.6%) had adenocarcinoma histology. The median number of cycles administered was 6, and the objective response rate was 40.7%. The median progression-free survival, overall survival and 1-year survival were 8.8 months, 27.2 months and 79%, respectively. The treatment was well-tolerated, and no treatment-related death was observed.

conclusionCombination chemotherapy with PEM plus Bev in elderly patients with previously untreated advanced non-squamous NSCLC exhibited favorable antitumor activity and tolerability, suggesting that a combination of PEM plus Bev might be a promising treatment option for this population.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBevacizumabHumansPemetrexedTreatment OutcomeBevacizumabPemetrexedbevacizumabelderly patientspemetrexedpreviously untreated nonsquamous non-small cell lung cancer

Identifiers

PMID37718463
PMCPMC10643789
OpenAlexW4386817843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.